Teva Pharmaceutical Industries Limited (TEVJF)
OTCMKTS · Delayed Price · Currency is USD
28.61
+2.61 (10.04%)
At close: Dec 9, 2025
TEVJF Revenue
Teva Pharmaceutical Industries had revenue of $4.48B in the quarter ending September 30, 2025, with 3.42% growth. This brings the company's revenue in the last twelve months to $16.78B, up 0.02% year-over-year. In the year 2024, Teva Pharmaceutical Industries had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
16.78B
Revenue Growth
+0.02%
P/S Ratio
2.17
Revenue / Employee
482.22K
Employees
35,686
Market Cap
36.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | 16.89B | -1.38B | -7.57% |
| Dec 31, 2018 | 18.27B | -3.58B | -16.39% |
| Dec 31, 2017 | 21.85B | -50.00M | -0.23% |
| Dec 31, 2016 | 21.90B | 2.25B | 11.45% |
| Dec 31, 2015 | 19.65B | -620.00M | -3.06% |
| Dec 31, 2014 | 20.27B | -42.00M | -0.21% |
| Dec 31, 2013 | 20.31B | -3.00M | -0.01% |
| Dec 31, 2012 | 20.32B | 2.01B | 10.95% |
| Dec 31, 2011 | 18.31B | 2.19B | 13.59% |
| Dec 31, 2010 | 16.12B | 2.22B | 15.99% |
| Dec 31, 2009 | 13.90B | 2.81B | 25.39% |
| Dec 31, 2008 | 11.09B | 1.68B | 17.83% |
| Dec 31, 2007 | 9.41B | 1.00B | 11.89% |
| Dec 31, 2006 | 8.41B | 3.16B | 60.15% |
| Dec 31, 2005 | 5.25B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
Teva Pharmaceutical Industries News
- 1 day ago - Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade) - Seeking Alpha
- 3 days ago - Piper Sandler Elevates TEVA Price Target to $40 with Overweight Rating | TEVA Stock News - GuruFocus
- 5 days ago - Goldman Sachs Raises TEVA Price Target to $35, Maintains Buy Rating | TEVA Stock News - GuruFocus
- 6 days ago - Insider Selling: Amir Weiss Unloads $371K Of Teva Pharmaceutical Indus Stock - Benzinga
- 6 days ago - Alvotech, Teva Secures U.S. License Entry Date For Eylea Biosimilar AVT06 - Nasdaq
- 6 days ago - Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S. - Seeking Alpha
- 6 days ago - Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® - GlobeNewsWire
- 6 days ago - My Top 10 Portfolio Holdings for 2026 - The Motley Fool